Every material Form 8-K Sonoma Pharmaceuticals, Inc. has filed with the SEC since April 30, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Sonoma Pharmaceuticals entered into a new Section 382 rights agreement with Computershare on October 6, 2026, replacing its 2016 rights plan, which expires October 18, 2026. The plan is meant to guard against an ownership change that could substantially limit the company's ability to use its net operating loss carryforwards and other tax benefits, which the company says could be a substantial asset.
Rights dividend of one preferred stock purchase right per common share held on October 13, 2026 (Record Date)
Each right allows purchase of one one-thousandth of a Series B Preferred Stock share at $10.00, subject to adjustment
Rights become exercisable if a person or group acquires 4.99% or more of common stock, and expire October 6, 2036 unless earlier redeemed
Board may redeem rights at $0.0001 per right before a person becomes an Acquiring Person
Sonoma Pharmaceuticals filed a prospectus supplement increasing the aggregate offering price under its at-the-market share sales agreement with Ladenburg Thalmann to $3,641,703. Since September 26, 2025, the company has sold 173,073 shares for $574,633, so the larger amount gives it room to raise more equity from the program, which could dilute existing shareholders.
Shares sold under the agreement from September 26, 2025 through the filing date: 173,073 shares for $574,633
Aggregate offering price raised to $3,641,703 via a supplement filed June 18, 2026
Shares previously registered but not yet sold total $1,495,830
Sonoma Pharmaceuticals sold shares, pre-funded warrants and warrants in a public offering priced at $1.35 per unit, with the offering closing on April 27 and 28, 2026, including full exercise of the underwriter's over-allotment option. The company expects net proceeds of about $3.5 million, and the filing also discloses warrants that could bring in additional cash, which adds potential share dilution for existing shareholders.
Priced April 24, 2026 at $1.35 per unit; closed April 27 and 28, 2026, with full exercise of the 45-day over-allotment option.
Issued 1,650,716 common shares, 1,312,247 pre-funded warrants and 3,407,404 warrants exercisable at $1.35 per share, expiring on the fifth anniversary of issuance.
Net proceeds expected to be about $3.5 million after a 7.5% underwriting fee, a 1% expense allowance and other offering expenses.
Underwriter warrant for up to 5% of securities sold; the company and its officers and directors agreed to a 90-day restriction on sales, subject to limited exceptions.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Sonoma Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →